Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 303-308

  Kowalczyk, Keith J ^a   Gu, Xiangmei ^b   Nguyen, Paul L ^c   Lipsitz, Stuart R ^b   Trinh, Quoc Dien ^d,e   Lynch, John H ^a   Collins, Sean P ^a   Hu, Jim C ^f  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Outcomes; Prostate cancer; Radiation therapy; Radical prostatectomy; SEER

Indexed keywords

ADJUVANT RADIOTHERAPY; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER SPECIFIC MORTALITY; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; THERAPY DELAY; TIME TO TREATMENT; URETHRA STRICTURE; URINE INCONTINENCE; ADJUVANT THERAPY; CANCER REGISTRY; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS;

AGED; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SEER PROGRAM;

EID: 84897084051     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.004     Document Type: Article

References (30)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004, 22:2141-2149.
3. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998, 280:969-974.
4. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004, 171:1393-1401.
5. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517-523.
6. Van der Kwast T., Bolla M., Van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007, 25:4178-4186.
7. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
8. Thompson I., Tangen C., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
9. Thompson I., Tangen C., Klein E. Is there a standard of care for pathologic stage T3 prostate cancer?. J Clin Oncol 2009, 27:2898-2899.
10. Koch M.O. Should the patient with positive margins after radical prostatectomy receive adjuvant radiation?. J Urol 2010, 184:1838-1839.
11. Moinpour C.M., Hayden K.A., Unger J.M., et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008, 26:112-120.
12. Potosky A.L., Riley G.F., Lubitz J.D., Mentnech R.M., Kessler L.G. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993, 31:732-748.
13. Zippin C., Lum D., Hankey B.F. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995, 76:2343-2350.
14. Klabunde C.N., Potosky A.L., Legler J.M., Warren J.L. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000, 53:1258-1267.
15. Wright J.L., Dalkin B.L., True L.D., et al. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010, 183:2213-2218.
16. Krupski T.L., Smith M.R., Chan Lee W., et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004, 101:541-549.
17. Hu J.C., Gu X., Lipsitz S.R., et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. J Am Med Assoc 2009, 302:1557-1564.
18. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127(8 Part 2):757-763.
19. Robins J.M., Hernán M.Á., Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11:550-560.
20. Mazumdar M., Glassman J.R. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision making about cancer treatments. Stat Medi 2000, 19:113-132.
21. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578.
22. Thompson I., Tangen C., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. J Am Med Assoc 2006, 296:2329-2335.
23. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. J Am Med Assoc 2008, 299:2760-2769.
24. Weinfurt K.P., Li Y., Castel L.D., et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005, 16:579-584.
25. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
26. Herr H.W., O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000, 163:1743-1746.
27. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001, 19:3750-3755.
28. Menon M., Bhandari M., Gupta N., et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol 2010, 58:838-846.
29. Yu J.B., Lackland A.F.B., Many S. NCI SEER public-use data: applications and limitations in oncology research. Oncology 2009, 23:288-295.
30. Virnig B.A., Warren J.L., Cooper G.S., Klabunde C.N., Schussler N., Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002, 40:49-54. [IV].